Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Chi-Med to Announce 2020 Final Results
02:00am, Wednesday, 03'rd Feb 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
05:00am, Thursday, 14'th Jan 2021
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inm
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
03:08pm, Sunday, 03'rd Jan 2021
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
07:00am, Wednesday, 30'th Dec 2020
– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China –
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
01:25pm, Monday, 28'th Dec 2020
– Company plans to complete rolling submission in the first half of 2021 –
Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference
02:00am, Tuesday, 22'nd Dec 2020
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Ex
Chi-Med Announces US$100 Million Equity Investment by CPP Investments
02:00am, Tuesday, 17'th Nov 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
04:00am, Thursday, 05'th Nov 2020
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the
AbbVie I-Mab Cancer Deal, And Other News: The Good, Bad And Ugly Of Biopharma
04:46am, Tuesday, 08'th Sep 2020
AbbVie inks multi-billion cancer deal with I-Mab. Chi-Med begins global phase III trial of cancer treatment.
Edison issues ADR update on Hutchison China MediTech (HCM)
01:10pm, Monday, 10'th Aug 2020
LONDON, UK / ACCESSWIRE / August 10, 2020 / Hutchison China MediTech (NASDAQ:HCM) continues to move swiftly towards its goal of globalization of its innovative oncology assets and building a fully int
Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
06:00am, Monday, 10'th Aug 2020
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice f
Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
07:29am, Sunday, 02'nd Aug 2020
Hutchison China MediTech Limited (NASDAQ:HCM) Q2 2020 Results Earnings Conference Call July 30, 2020, 08:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Wei-guo Su - Executive D
Hutchison China MediTech Limited (HCM) Q2 2020 Earnings Call Transcript
03:01am, Friday, 31'st Jul 2020
Image source: The Motley Fool. Hutchison China MediTech Limited (NASDAQ: HCM)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prep
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
12:47pm, Thursday, 30'th Jul 2020
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further
